An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

ABT-925

DRUG

Placebo

Trial Locations (18)

1900

Site Reference ID/Investigator# 5224, La Plata

30308

Site Reference ID/Investigator# 4168, Atlanta

33161

Site Reference ID/Investigator# 4177, North Miami

44280

Site Reference ID/Investigator# 4305, Guadalajara

77401

Site Reference ID/Investigator# 4371, Bellaire

78754

Site Reference ID/Investigator# 4567, Austin

78756

Site Reference ID/Investigator# 4176, Austin

90660

Site Reference ID/Investigator# 4553, Pico Rivera

90703

Site Reference ID/Investigator# 4539, Cerritos

91786

Site Reference ID/Investigator# 4565, Upland

92126

Site Reference ID/Investigator# 4173, San Diego

92805

Site Reference ID/Investigator# 5188, Anaheim

92845

Site Reference ID/Investigator# 4175, Garden Grove

CP1425

Site Reference ID/Investigator# 5227, Buenos Aires

X5009BIN

Site Reference ID/Investigator# 5226, Córdoba

CP 03740

Site Reference ID/Investigator# 4304, Mexico City

CP 14000

Site Reference ID/Investigator# 4303, Mexico City

CP 64000

Site Reference ID/Investigator# 4298, Monterrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY